Advertisement
Screener

NOVAVAX INC (NVAX) Total Long-Term Debt

2.8 / 5 stars · 68/120 Roast Me

NOVAVAX INC Total Long-Term Debt

NOVAVAX INC (NVAX) had Total Long-Term Debt of $291.49 million as of 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified

us-gaap:LongTermDebt · last filed 2026-08-06

  • 2026-06-30: Long-term Debt $291.49M.
  • 2026-03-31: Long-term Debt $291.04M.
  • 2025-12-31: Long-term Debt $244.21M.
Period endLong-term Debt
2026-06-30$291.49M
10-Q · filed 2026-08-06
2026-03-31$291.04M
10-Q · filed 2026-05-06
2025-12-31$244.21M
10-Q · filed 2026-08-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Immunocore Holdings plc (IMCR)$1.613B-90.43
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
Vericel Corp (VCEL)United States$2.011B93.97
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16